Alector Crescita futura

Future criteri di controllo 5/6

Alector prevede che gli utili e i ricavi cresceranno rispettivamente di 38.8% e 40.2% all'anno. Si prevede che l'EPS crescerà di 43.3% all'anno. Si prevede che il ritorno sul capitale proprio sarà di -150.9% in 3 anni.

Informazioni chiave

38.8%

Tasso di crescita degli utili

43.29%

Tasso di crescita dell'EPS

Biotechs crescita degli utili	23.6%
Tasso di crescita dei ricavi	40.2%
Rendimento futuro del capitale proprio	-150.93%
Copertura analitica	Good
Ultimo aggiornamento	13 May 2025

Aggiornamenti recenti sulla crescita futura

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

Recent updates

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

May 11

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

May 05

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Apr 03 Alector's ABC platform and late-stage trials, like those for latozinemab, could significantly boost revenue if successful, addressing unmet medical needs.

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Mar 21

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Mar 13

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Dec 23

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Nov 28

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

May 11

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Mar 01

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Jan 19

Alector: Good Data, Huge Cash, No Near Term Catalyst

Jan 16

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Sep 25

Here's Why We're Not Too Worried About Alector's (NASDAQ:ALEC) Cash Burn Situation

Jun 27

Analysts Are Betting On Alector, Inc. (NASDAQ:ALEC) With A Big Upgrade This Week

Mar 02

Alector (NASDAQ:ALEC) Is In A Good Position To Deliver On Growth Plans

Jan 16

Alector: Advancement Of Third Alzheimer's Drug Brings About Huge Potential

Oct 04

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:ALEC - Stime future degli analisti e dati finanziari passati (USD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
12/31/2027	96	-125	-131	-93	5
12/31/2026	59	-161	-122	-108	7
12/31/2025	12	-178	-101	-91	7
3/31/2025	88	-123	-230	-229	N/A
12/31/2024	101	-119	-231	-230	N/A
9/30/2024	62	-158	-222	-221	N/A
6/30/2024	55	-161	-218	-217	N/A
3/31/2024	96	-121	-199	-197	N/A
12/31/2023	97	-130	-187	-184	N/A
9/30/2023	96	-141	-190	-187	N/A
6/30/2023	102	-143	-194	-190	N/A
3/31/2023	126	-135	-208	-204	N/A
12/31/2022	134	-133	-24	-20	N/A
9/30/2022	133	-136	-25	-21	N/A
6/30/2022	301	36	471	473	N/A
3/31/2022	227	-29	483	486	N/A
12/31/2021	207	-36	295	299	N/A
9/30/2021	198	-33	297	300	N/A
6/30/2021	21	-212	-189	-186	N/A
3/31/2021	18	-202	-190	-187	N/A
12/31/2020	21	-190	-172	-167	N/A
9/30/2020	22	-169	-154	-148	N/A
6/30/2020	19	-148	-144	-136	N/A
3/31/2020	23	-127	-125	-108	N/A
12/31/2019	21	-105	-115	-99	N/A
9/30/2019	24	-92	-102	-88	N/A
6/30/2019	28	-76	-94	-82	N/A
3/31/2019	28	-62	-84	-81	N/A
12/31/2018	28	-52	N/A	127	N/A
9/30/2018	22	-45	N/A	143	N/A
6/30/2018	15	-39	N/A	159	N/A
3/31/2018	8	-35	N/A	171	N/A
12/31/2017	4	-32	N/A	-18	N/A
12/31/2016	0	-15	N/A	-13	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Si prevede che ALEC diventerà redditizio nei prossimi 3 anni, il che è considerato una crescita più rapida del tasso di risparmio ( 2.9% ).

Guadagni vs Mercato: Si prevede che ALEC diventerà redditizia nei prossimi 3 anni, il che è considerato una crescita superiore alla media del mercato.

Guadagni ad alta crescita: Si prevede ALEC diventerà redditizia nei prossimi 3 anni.

Ricavi vs Mercato: Si prevede che il fatturato di ALEC ( 40.2% all'anno) crescerà più rapidamente del mercato US ( 8.5% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di ALEC ( 40.2% all'anno) crescerà più rapidamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Si prevede che ALEC non sarà più redditizia tra 3 anni.

Scoprire le aziende in crescita

Analisi aziendale e situazione dei dati finanziari

Dati	Ultimo aggiornamento (ora UTC)
Analisi dell'azienda	2025/06/01 18:51
Prezzo dell'azione a fine giornata	2025/05/30 00:00
Guadagni	2025/03/31
Guadagni annuali	2024/12/31

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

Pacchetto	Dati	Tempistica	Esempio Fonte USA ^*
Dati finanziari della società	10 anni	Conto economico Rendiconto finanziario Bilancio	Modulo SEC 10-K Modulo SEC 10-Q
Stime di consenso degli analisti	+3 anni	Previsioni finanziarie Obiettivi di prezzo degli analisti	Rapporti di ricerca degli analisti Blue Matrix
Prezzi di mercato	30 anni	Prezzi delle azioni Dividendi, scissioni e azioni	Dati di mercato ICE Modulo SEC S-1
Proprietà	10 anni	Top azionisti Insider trading	Modulo 4 SEC Modulo 13D SEC
Gestione	10 anni	Team di leadership Consiglio di amministrazione	Modulo SEC 10-K Modulo SEC DEF 14A
Sviluppi principali	10 anni	Annunci aziendali	Modulo 8-K SEC

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Alector, Inc. è coperta da 15 analisti. 7 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

Analista	Istituzione
Alec Stranahan	BofA Global Research
Thomas Shrader	BTIG
Pete Stavropoulos	Cantor Fitzgerald & Co.

Alector Crescita futura

Future criteri di controllo 5/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Recent updates

Consensus revenue estimates decrease by 14%, EPS upgraded

US$5.26 - That's What Analysts Think Alector, Inc. (NASDAQ:ALEC) Is Worth After These Results

First quarter 2025 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. (NASDAQ:ALEC) Stock Catapults 27% Though Its Price And Business Still Lag The Industry

Alector, Inc., Annual General Meeting, Jun 11, 2025

New minor risk - Share price stability

Alector Announces Completion of Enrollment in the PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Individuals with Early Alzheimer’s Disease

New minor risk - Market cap size

ABC Platform And Latozinemab Trial Will Yield Mixed Prospects

Alector Provides Executive Leadership Update

Alector, Inc. (NASDAQ:ALEC) Not Doing Enough For Some Investors As Its Shares Slump 26%

Alector: Q4 Of 2025 FTD-GRN Treatment Data Is Important Inflection Point

Co-Founder recently sold US$59k worth of stock

Price target decreased by 7.9% to US$4.22

Consensus revenue estimates fall by 67%

Co-Founder notifies of intention to sell stock

Earnings Update: Alector, Inc. (NASDAQ:ALEC) Just Reported And Analysts Are Trimming Their Forecasts

Full year 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. Provides Revenue Guidance for the Year Ending 2025

Insufficient new directors

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 53%

Price target decreased by 22% to US$6.33

Co-Founder recently sold US$131k worth of stock

Co-Founder notifies of intention to sell stock

Need To Know: Analysts Just Made A Substantial Cut To Their Alector, Inc. (NASDAQ:ALEC) Estimates

Alector: Bleak Prospects After Alzheimer's Failure

Price target decreased by 37% to US$10.28

Alector, Inc. Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’S Disease and Provides Business Update

Alector, Inc. announced that it expects to receive $50 million in funding from Hercules Capital, Inc., and other investors

Third quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc.'s (NASDAQ:ALEC) Business And Shares Still Trailing The Industry

We Think Alector (NASDAQ:ALEC) Needs To Drive Business Growth Carefully

New minor risk - Share price stability

Alector, Inc. Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

Co-Founder recently sold US$129k worth of stock

Co-Founder recently sold US$129k worth of stock

Board Member recently sold US$228k worth of stock

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)

Alector, Inc.'s (NASDAQ:ALEC) Price Is Right But Growth Is Lacking

Co-Founder recently sold US$121k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. (NASDAQ:ALEC) First-Quarter Results: Here's What Analysts Are Forecasting For This Year

Alector, Inc. Reiterates Revenue Guidance for the Year Ending 2024

First quarter 2024 earnings released: US$0.39 loss per share (vs US$0.55 loss in 1Q 2023)

Alector, Inc., Annual General Meeting, Jun 12, 2024

Co-Founder recently sold US$130k worth of stock

Consensus revenue estimates decrease by 37%, EPS upgraded

Co-Founder notifies of intention to sell stock

Analysts Are Updating Their Alector, Inc. (NASDAQ:ALEC) Estimates After Its Full-Year Results

Alector, Inc. Provides Revenue Guidance for the Year Ending 2024

New major risk - Revenue and earnings growth

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Alector, Inc. to Report Fiscal Year 2023 Results on Feb 27, 2024

Alector Announces First Patient Dosed in Progress-Ad Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’S Disease

The Market Doesn't Like What It Sees From Alector, Inc.'s (NASDAQ:ALEC) Revenues Yet As Shares Tumble 27%

Alector, Inc. has completed a Follow-on Equity Offering in the amount of $71.413049 million.

New minor risk - Shareholder dilution

Alector, Inc. has filed a Follow-on Equity Offering.

Alector: Good Data, Huge Cash, No Near Term Catalyst

Insufficient new directors

New major risk - Revenue and earnings growth

Co-Founder recently sold US$133k worth of stock

Co-Founder notifies of intention to sell stock

Alector, Inc. has filed a Follow-on Equity Offering in the amount of $125 million.

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Alector, Inc. Reiterates Earnings Guidance for the Year Ending 2023

Alector, Inc. Announces Achievement of Target Enrollment in the Pivotal INFRONT-3 Phase 3 Clinical Trial of Latozinemab in Individuals with Frontotemporal Dementia Due to Progranulin Gene Mutation (FTD-GRN)